InvestigationsGLP-1s & peptides
Ozempic, GLP-1s & knockoff peptides
Blueshoe is investigating the full GLP-1 economy: brand drugs linked in consolidated lawsuits to vision loss and stomach paralysis, compounded and counterfeit peptides sold by med spas, telehealth sites, and online vendors — and the changes users report to mood, desire, and daily life. If these drugs seriously harmed your health or your life, you may be eligible to have your potential claim evaluated.
WHAT WE ARE INVESTIGATING
Blockbuster drugs, a gray-market copy industry — and effects the labels never mentioned.
These are the consolidated court proceedings, regulatory actions, and published findings this investigation builds on.
Why are GLP-1 users suing over sudden vision loss?
NAION — a stroke of the optic nerve causing sudden, usually permanent vision loss. A 2024 JAMA Ophthalmology study reported elevated NAION risk in semaglutide users, European regulators added it to the label in 2025, and in December 2025 federal courts created a dedicated consolidated proceeding (MDL 3163) that is growing month over month.
What is the stomach-paralysis litigation?
Nearly 4,000 cases are consolidated in federal court (MDL 3094) alleging Novo Nordisk and Eli Lilly failed to warn about gastroparesis — delayed stomach emptying — as well as ileus and intestinal obstruction. The court now requires gastroparesis claims to be supported by an objective gastric emptying study, which is why our criteria below are specific.
What about compounded semaglutide and “research peptides”?
A separate front with different defendants. The FDA has logged hundreds of adverse-event reports tied to compounded semaglutide and tirzepatide — many involving dosing errors from multidose vials, some requiring hospitalization — plus counterfeit products naming pharmacies that don't exist. Since the shortages ended in early 2025, most mass compounding lost its legal basis, yet med spas, telehealth platforms, and online peptide vendors kept selling.
Regulators are moving: the FDA issued dozens of warning letters to telehealth companies and peptide vendors, and state attorneys general in California, Texas, New York, and Massachusetts opened investigations into direct-to-consumer weight-loss platforms. If a compounded or gray-market product hurt you, the seller — not just the drugmaker — may be responsible.
Can these drugs take away desire, pleasure, or connection?
A growing number of users and clinicians report exactly that — emotional flattening, lost libido, lost interest in hobbies, food, and relationships — enough that “Ozempic personality” has become shorthand. Published case reports exist, and researchers point to a plausible mechanism: these drugs quiet the brain's dopamine reward system. No controlled trial has yet measured it, and courts don't yet recognize it — so this investigation is documenting these reports now, while the science catches up.
Two related, documented risks: pulmonary aspiration during surgery or anesthesia (label updated late 2024), and an FDA-reviewed signal on suicidal thoughts that this investigation continues to monitor.
WHO MAY QUALIFY
You may be eligible to have your potential claim evaluated if:
Objective criteria matched to what courts recognize today — plus a wide door for what they may recognize next. Every submission is evaluated, free.
Vision loss (NAION)
Diagnosed by an ophthalmologist with NAION or sudden optic-nerve-related vision loss after taking any GLP-1 drug — brand, compounded, or gray-market.
Gastroparesis with testing
Gastroparesis confirmed by a gastric emptying study performed while symptomatic, plus emergency or hospital treatment.
Bowel obstruction or ileus
Hospitalized for an intestinal obstruction or ileus while on (or shortly after stopping) a GLP-1 drug.
Aspiration during a procedure
Suffered pulmonary aspiration during surgery or anesthesia while taking a GLP-1 drug.
Harmed by a compounded or knockoff peptide
Hospitalized or seriously harmed after using compounded semaglutide or tirzepatide, or a peptide bought from a med spa, telehealth site, or online vendor — including dosing errors, contaminated or mislabeled product.
Other serious health or life effects
Severe mood changes, suicidal thoughts, or a profound loss of desire, pleasure, or connection that changed your life while on these drugs. Courts haven't recognized every harm yet — documenting yours now is how that changes.
WHAT HAPPENS IF YOU CONTACT US
Four steps. No surprises.
Short questionnaire
You share contact information and basic facts only — no detailed medical records or narratives at this stage.
Conflicts check
We confirm the firm can ethically evaluate your potential claim.
Investigation agreement
If your information meets the criteria, we may offer a limited-scope investigation agreement — an agreement for us to investigate and evaluate a potential claim. Signing it does not mean a lawsuit has been or will be filed.
Next steps, together
If and when a viable claim is developed, we contact you to discuss next steps — which may include associating with a lawyer licensed in your state.
No fee unless you recover
There is no cost to submit your information. If we agree to represent you, representation is on a contingency-fee basis — no attorneys’ fee unless there is a recovery. You may remain responsible for costs in some circumstances; the written agreement controls.
Common questions
Novo Nordisk's semaglutide and liraglutide drugs — Ozempic, Wegovy, Rybelsus, Saxenda, Victoza — Eli Lilly's Mounjaro and Zepbound, and the copy economy around them: compounded versions from pharmacies, med spas, and telehealth platforms, and “research peptide” products sold online. Compounded and gray-market products often mean different defendants — the seller, not just the manufacturer.
Legally reviewed by Catherine O’Grady, State Bar of Arizona No. 011647
Managing partner & chief compliance officer · 30+ years in practice · Reviewed July 2026 · Full bio →
Required disclosures
Attorney Advertising. This page is a communication about legal services from Blueshoe Legal Services PLLC, 5227 N 7th St #94743, Phoenix, AZ 85014. Responsible attorney: Catherine O'Grady, licensed in Arizona. Blueshoe's attorneys are licensed only in the jurisdictions listed on this site. This page is not legal advice.
No attorney-client relationship. Submitting information through this page does not create an attorney-client relationship and does not make you a client of Blueshoe. An attorney-client relationship is formed only by a written agreement signed by you and the firm. Do not include confidential or sensitive details in this form — provide only the information requested.
Deadlines. Legal claims are subject to strict time limits (statutes of limitations and repose) that vary by state and may expire soon. Submitting this form does not stop any deadline. If you believe you have a claim, you should promptly consult a lawyer licensed in your state.
No guarantee. Prior results do not guarantee a similar outcome. We cannot and do not promise any particular result. Verdicts, settlements, and case outcomes described on this page are from litigation in which Blueshoe was not counsel of record; they are reported from public sources to describe the litigation landscape, not as results obtained by this firm.
Allegations, not findings. References on this page to the conduct of any company or product describe allegations made in publicly filed lawsuits, regulatory actions, or published research, attributed to their sources. Except where a court judgment or regulatory finding is expressly identified as such, nothing on this page asserts that any named company has been found liable or has violated any law.
Co-counsel. Blueshoe may associate with, or refer your matter to, other law firms, including lawyers licensed in your state. Any fee division will comply with applicable rules and, where required, will be disclosed to you and made only with your written consent at no increase in your total fee.